NinaMED Secures $13.75M Funding to Propel NiNA System for OAB Therapy

NinaMED's Innovative Approach to Overactive Bladder Therapy

NinaMED Pty Ltd, a new player in the medtech arena based in Melbourne, Australia, has made headlines with its recent announcement of securing $13.75 million in financing. The funding is aimed at advancing the NiNA System®, a groundbreaking, non-invasive therapy designed for patients dealing with overactive bladder (OAB) symptoms, an issue impacting an estimated 550 million people worldwide.

The financing round was led by SPRIM Global Investments, a venture capital firm specializing in clinical-stage life sciences. This significant investment not only marks a pivotal moment for NinaMED but also underscores the growing recognition of the need for innovative solutions to address pelvic health disorders.

What is the NiNA System®?

The NiNA System® is a sophisticated, wearable neuromodulation device that provides a drug-free treatment option at home. By focusing on a non-invasive approach, it aims to eliminate the discomfort and risks associated with traditional treatments like anticholinergic medications and invasive procedures. The device works by targeting the saphenous nerve in the upper calf, using a patented technology developed by EBT Medical, a Toronto-based company that has granted NinaMED exclusive licensing rights to this technology.

NinaMED's innovative treatment allows patients to handle their care in the comfort of their own homes, alleviating the challenges of frequent clinic visits for injections or other procedures.